Amyloid Storm: An Uncommon Case of AA Amyloid Nephropathy
DOI:
https://doi.org/10.71749/pkj.81Keywords:
Acute Kidney Injury, Amyloidosis, Nephrotic Syndrome, Serum Amyloid A ProteinAbstract
AA amyloidosis is a rare disease caused by tissue accumulation of serum amyloid A (SAA), a protein produced in the liver
in response to chronic inflammation or infection. Kidney manifestations of AA amyloidosis usually develop gradually.
The authors report a case of a 77‑year‑old patient with a previous diagnosis of multifactorial chronic kidney disease and
bronchiectasis, who developed sudden onset nephrotic syndrome and KDIGO stage 3 acute kidney injury shortly after
the diagnosis of acute pyelonephritis. A kidney biopsy confirmed the diagnosis of renal AA amyloidosis. Progressive
kidney dysfunction ensued, with the need to begin kidney replacement therapy eleven months after the initial diagnosis.
This type of renal AA amyloidosis (referred to as “amyloid storm”) has been reported in patients with familial Mediterra‑
nean fever but was not previously described in AA amyloidosis of other etiologies. The prognosis is poor, especially after
dialysis initiation, and more studies are needed to develop strategies to delay its progression and improve outcomes.
Downloads
References
Dember LM. Amyloidosis‑associated kidney disease. J Am Soc Nephrol. 2006;17:3458–71. doi: 10.1681/ASN.2006050460.
Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–71. doi: 10.1056/NEJMoa070265.
Pepys MB. Amyloidosis. Annu Rev Med. 2006;57:223–41. doi: 10.1146/annurev.med.57.121304.131243.
Kukuy OL, Beckerman P, Dinour D, Ben‑Zvi I, Livneh A. Amyloid storm: acute kidney injury and massive proteinuria, rapidly progressing to end‑stage kidney disease in AA amyloidosis of familial Mediterranean fever. Rheumatology. 2020;60:3235–42. doi: 10.1093/rheumatology/keaa772.
Ayar Y, Ersoy A, Oksuz MF, Ocakoglu G, Vuruskan BA, Yildiz A, et al. Desfechos clínicos e sobrevida em pacientes com amiloidose AA. Rev Bras Reum. 2017;57:535–44.
Verine J, Mourad N, Desseaux K, Vanhille P, Noël LH, Beaufils H, et al. Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid‑associated inflammatory response. Hum Pathol. 2007;38:1798–809. doi: 10.1016/j.humpath.2007.04.013.
Erdogmus S, Celebi ZK, Akturk S, Kumru G, Duman N, Ates K, et al. Profile of renal AA amyloidosis in older and younger individuals: a single‑centre experience. Amyloid. 2018;25:115–9. doi: 10.1080/13506129.2018.1474733.
Mirioglu S, Uludag O, Hurdogan O, Kumru G, Berke I, Doumas SA, et al. AA Amyloidosis: A Contemporary View. Curr Rheumatol Rep. 2024;26:248–59. doi: 10.1007/s11926‑024‑01147‑8.
Picken MM. The pathology of amyloidosis in classification: a review. Acta Haematol. 2020;143:322–34. doi:10.1159/000506696.
Said SM, Sethi S, Valeri AM, Leung N, Cornell LD, Fidler ME, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013;8:1515–23. doi: 10.2215/CJN.10491012.
Hutten H von, Mihatsch M, Lobeck H, Rudolph B, Eriksson M, Röcken C. Prevalence and origin of amyloid in kidney biopsies. Am J Surg Pathol. 2009;33:1198–205. doi: 10.1097/PAS.0b013e3181abdfa7.
Oliveira‑Silva C, Marques N, Pinho A, Poínhos R, Bergantim R, Nunes AT, et al. Lessons from four decades of systemic amyloidosis with renal involvement. Nephron. 2023;147:158–69. doi: 10.1159/000525675.
Muchtar E, Dispenzieri A, Magen H, Grogan M, Mauermann M, McPhail ED, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2021;289:268–92. doi: 10.1111/joim.13169.
Keeling J, Teng J, Herrera GA. AL‑amyloidosis and light‑chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Investig. 2004;84:1322–38. doi: 10.1038/labinvest.3700161.
Çelebi ZK , Kiremitçi S , Sadioğlu RE , Keven K. Rapidly Progressive Renal Failure in AA Amyloidosis: A New Clinical and Histopathological Entity for an Old Disease. Turk J Nephrol. 2020;29:289–96. doi: 10.5152/turkjnephrol.2020.4221.
Merlini G, Bellotti V. Molecular Mechanisms of Amyloidosis. N Engl J Med. 2003;349:583–96. doi: 10.1056/NEJMra023144.
Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50:1700629. doi: 10.1183/13993003.00629‑2017.
Malle E, Steinmetz A, Raynes JG. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis. 1993;102:131–46.
Karam S, Haidous M, Royal V, Leung N. Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review. Kidney Int. 2023;103:473–84. doi: 10.1016/j.kint.2022.10.028.
Yilmaz M, Unsal A, Sokmen M, Kaptanogullari OH, Alkim C, Kabukcuoglu F, et al. Renal Involvement in AA Amyloidosis: linical Outcomes and Survival. Kidney Blood Press Res. 2013;37:33–42. doi: 10.1159/000343398.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Diogo Domingos, Ivo Laranjinha, Rita Theias Manso, Patrícia Matias, Margarida Gonçalves (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
